Literature DB >> 34279791

Transient altered mental status and leptomeningeal enhancement associated with pembrolizumab: a case report.

Keng Lam1, Sameer K Kulkarni2, Manya Khrlobyan3, Pamela K Cheng4, Caroline L Fong5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34279791     DOI： 10.1007/s10072-021-05479-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  6 in total

1.  Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study.

Authors:  S Galmiche; C Lheure; N Kramkimel; N Franck; F Boitier; N Dupin; G Turc; D Psimaras; S Aractingi; S Guégan
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-07-26       Impact factor: 6.166

Review 2.  Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.

Authors:  Sophie Feng; Jermaine Coward; Elizabeth McCaffrey; John Coucher; Paul Kalokerinos; Ken O'Byrne
Journal:  J Thorac Oncol       Date:  2017-08-24       Impact factor: 15.609

3.  Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma.

Authors:  Kogenta Nakamura; Hiroshi Saiki; Hiroyuki Muramatsu; Shingo Morinaga; Ikuo Kobayashi; Keishi Kajikawa; Genya Nishikawa; Yoshiharu Kato; Masahito Watanabe; Kent Kanao; Makoto Sumitomo
Journal:  Int Cancer Conf J       Date:  2017-08-02

4.  Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.

Authors:  Kerry L Reynolds; Amanda C Guidon
Journal:  Oncologist       Date:  2018-11-27

5.  Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.

Authors:  Maiko Niki; Aya Nakaya; Takayasu Kurata; Kahori Nakahama; Hiroshige Yoshioka; Toshihiko Kaneda; Kayoko Kibata; Makoto Ogata; Shosaku Nomura
Journal:  Mol Clin Oncol       Date:  2018-11-27

6.  Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.

Authors:  Peng-Fei Wang; Yang Chen; Si-Ying Song; Ting-Jian Wang; Wen-Jun Ji; Shou-Wei Li; Ning Liu; Chang-Xiang Yan
Journal:  Front Pharmacol       Date:  2017-10-18       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.